Third, Vertex still has an exciting pipeline in CF and elsewhere. For instance, the company's late-stage candidate for APOL-1 ...

Vertex Pharmaceuticals today announced that Health Canada has granted Marketing Authorization for PrALYFTREKTM ...

Currently, the analyst consensus on Vertex Pharmaceuticals is a Moderate Buy with an average price target of $490.71, which is an 11.59% upside from current levels.